“We are dropping coverage of Bioverativ , Inc. following the completion of its acquisition by Sanofi (SNY $39.90). Our final rating on Bioverativ was Market Perform.”,” William Blair’s analyst wrote.
Several other analysts have also commented on BIVV. Credit Suisse Group reiterated a neutral rating on shares of Bioverativ in a report on Wednesday, January 24th. Argus reiterated a hold rating on shares of Bioverativ in a report on Wednesday, January 24th. Deutsche Bank set a $53.00 price objective on Bioverativ and gave the company a hold rating in a report on Monday, November 20th. Piper Jaffray Companies lowered Bioverativ from an overweight rating to a neutral rating in a report on Monday, January 22nd. Finally, Royal Bank of Canada increased their price objective on Bioverativ to $68.00 and gave the company a market perform rating in a report on Thursday, January 18th. Thirteen analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and an average target price of $63.15.
Bioverativ (NASDAQ:BIVV) last posted its earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. The company had revenue of $328.70 million during the quarter, compared to analyst estimates of $325.89 million. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. analysts forecast that Bioverativ will post 3.82 earnings per share for the current fiscal year.
A number of hedge funds have recently modified their holdings of the stock. BlackRock Inc. raised its stake in Bioverativ by 16.9% in the 4th quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock worth $584,795,000 after acquiring an additional 1,567,638 shares during the last quarter. Old Mutual Global Investors UK Ltd. raised its stake in Bioverativ by 47.8% in the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 2,507,002 shares of the biotechnology company’s stock worth $135,177,000 after acquiring an additional 810,364 shares during the last quarter. Wells Fargo & Company MN purchased a new position in Bioverativ in the 3rd quarter worth $124,500,000. Jackson Square Partners LLC raised its stake in Bioverativ by 21.1% in the 4th quarter. Jackson Square Partners LLC now owns 2,107,110 shares of the biotechnology company’s stock worth $113,615,000 after acquiring an additional 366,503 shares during the last quarter. Finally, OppenheimerFunds Inc. raised its stake in Bioverativ by 147.1% in the 4th quarter. OppenheimerFunds Inc. now owns 1,434,200 shares of the biotechnology company’s stock worth $77,332,000 after acquiring an additional 853,853 shares during the last quarter. Institutional investors own 97.18% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3255944/bioverativ-bivv-stock-rating-reaffirmed-by-william-blair.html.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.